Beta-blockers in patients with liver cirrhosis: Pragmatism or perfection?
With increasing decompensation, hyperdynamic circulatory disturbance occurs in liver cirrhosis despite activation of vasoconstrictors. Here, the concept of a therapy with non-selective beta-blockers was established decades ago. They lower elevated portal pressure, protect against variceal hemorrhage...
Main Authors: | Tilman Sauerbruch, Martin Hennenberg, Jonel Trebicka, Robert Schierwagen |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-01-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2022.1100966/full |
Similar Items
-
Severe carvedilol toxicity without overdose – caution in cirrhosis
by: Satish Maharaj, et al.
Published: (2017-11-01) -
Editorial: Portal Hypertension in Cirrhosis: From Pathogenesis to Novel Treatments
by: Chandana B. Herath, et al.
Published: (2022-03-01) -
Beta-blockers in Prevention of Development of Varices and Variceal Bleeding in Cirrhosis: Current Management, Controversies, and Future Directions
by: Dhiraj Tripathi
Published: (2017-06-01) -
Immune changes over time and survival in patients with cirrhosis treated with non-selective beta-blockers: A prospective longitudinal study
by: Susana Almenara, et al.
Published: (2023-07-01) -
The use of nonselective beta blockers is a risk factor for portal vein thrombosis in cirrhotic patients
by: Rosa Zampino, et al.
Published: (2018-01-01)